Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Diabetes

Volumn 50, Issue 7, 2001, Pages 1588-1597

  Deacon, Carolyn F ^a   Danielsen, Patricia ^a   Klarskov, Letty ^a   Olesen, Mette ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; KETAMINE; MIDAZOLAM; PYRROLE DERIVATIVE; VALINE; VALINE PYRROLIDIDE; VALINE-PYRROLIDIDE;

ANESTHESIA; ANIMAL; ARTICLE; BLOOD; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; RADIOIMMUNOASSAY; SWINE;

ANESTHESIA; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; KETAMINE; MIDAZOLAM; PYRROLES; RADIOIMMUNOASSAY; SWINE; VALINE;

EID: 0035403058     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.7.1588     Document Type: Article

References (52)

1. Krarup T, Holst JJ, Larsen KL: Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 249:E195-E200, 1985
2. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
3. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
4. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach. J Biol Chem 271:23222-23229, 1996
5. Jörnvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V: Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 123:205-210, 1981
6. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinal Metab 85:3575-3581, 2000
7. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS: The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 115:1011-1018, 1984
8. Chap Z, O'Dorisio TM, Cataland S, Field JB: Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs. Dig Dis Sci 32:280-284, 1987
9. O'Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S: Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism 26:651-656, 1977
10. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA: Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg 148:732-735, 1984
11. Jorde R, Burhol PG, Gunnes P, Schulz TB: Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand J Gastroenterol 16:469-471, 1981
12. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
13. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670, 1998
14. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258, 1998
15. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331, 1999
16. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48: 385-389, 1999
17. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464, 1996
18. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
19. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L: Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306-1312, 1983
20. Krarup T, Holst JJ: The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9:35-46, 1984
21. Dyrberg T, Kofod H: Synthetic peptides as antigen. In Animal Virus Pathogenesis: A Practical Approach. Oldstone MBA, Ed. Oxford, IRL Press, 1980, p. 163-171
22. Ørskov C, Holst JJ, Seier Poulsen S, Kirkegaard P: Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:974-981, 1987
23. Ørskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
24. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
25. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 48:758-765, 1996
26. O'Harte FPM, Mooney MH, Kelly CMN, Flatt PR: Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol 165:639-648, 2000
27. Deacon CF, Hughes TE, Hoist JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769, 1998
28. Elovson J: Biogenesis of plasma membrane glycoproteins: purification and properties of two rat liver membrane glycoproteins. J Biol Chem 255:5807-15815, 1980
29. Lojda Z: Studies on dipeptidyl(amino)peptidase IV (glycyl-proline-naphthylamidase). II. Blood vessels. Histochemistry 59:153-166, 1979
30. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K: Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-156, 1995
31. Schmid R, Schusdziarra V, Aulehner R, Weigert N, Classen M: Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. Z Gastroenterol 28:280-284, 1990
32. Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828, 1973
33. Pederson RA: Gastric inhibitory polypeptide. In Gut Peptides: Biochemistry and Physiology. Walsh J, Dockray G, Eds. New York, Raven Press, 1994, p. 217-259
34. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI: Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133:2861-2870, 1993
35. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM: Functional GIP receptors are present on adipocytes. Endocrinology 139:4004-4007, 1998
36. O'Harte FPM, Gray AM, Flatt PR: Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 156:237-243, 1998
37. Hauner H, Glatting G, Kaminska D, Pfeiffer EF: Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 32:282-288, 1988
38. Oben J, Morgan L, Fletcher J, Marks V: Effect of the entero-pancreatic hormones gastric inhibitory polypeptide and glucagon-like peptide-1(7-36)amide on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130:267-272, 1991
39. Morgan LM: The role of gastrointestinal hormones in carbohydrate and lipid metabolism and homeostasis: effects of gastric inhibitory polypeptide and glucagon-like peptide-1. Biochem Soc Trans 26:216-222, 1998
40. Starich GH, Bar RS, Mazzaferri EL: GIP increases insulin receptor affinity and cellular sensitivity in adipocytes. Am J Physiol 249:E603-E607, 1985
41. Yip RGC, Wolfe MM: GIP biology and fat metabolism. Life Sci 66:91-103, 2000
42. Rose MT, Itoh F, Takahashi Y: Effect of glucose-dependent insulinotropic polypeptide on whole-body glucose utilization in sheep. Exp Physiol 83:783-792, 1988
43. Service FJ, Heiling VJ, Go VL, Rizza RA: Lack of effect of gastric inhibitory polypeptide on hepatic and extrahepatic insulin action. J Clin Endocrinol Metab 70:1398-1402, 1990
44. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107)amide] on endocrine secretion from pig pancreas, antrum and non-antral stomach. Endocrinology 123:2009-2013, 1988
45. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M: Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-1430, 1998
46. Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J: Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46:792-800, 1997
47. Bailey CJ, Wilkes LC, Conlon JM, Armstrong PH, Buchanan KD: Effects of gastric inhibitory polypeptide, vasoactive intestinal peptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinol 125:375-379, 1990
48. Opara EC, Go VL: Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells. Regul Pept 32:65-73, 1991
49. Pederson RA, Brown JC: Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 103:610-615, 1978
50. Taminato T, Seino Y, Go Y, Inoue Y, Kadowaki S: Synthetic gastric inhibitory polypeptide: stimulatory effect on insulin and glucagon secretion in the rat. Diabetes 26:480-484, 1977
51. Dupre J, Caussignac Y, McDonald TJ, Van Vliet S: Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. J Clin Endocrinol Metab 72:125-129, 1991
52. Asplin CM, Paquette TL, Palmer JP: In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 68:314-318, 1981